Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTMQB37)

DTT Name	Interferon alpha/beta receptor 2 (IFNAR2)
Synonyms	Type I interferon receptor 2; Type I interferon receptor; Interferon alpha/beta receptor; Interferon alpha binding protein; IFNARB; IFNABR; IFN-alpha/beta receptor 2; IFN-alpha-REC; IFN-alpha binding protein; IFN-R-2; IFN-R
Gene Name	IFNAR2
DTT Type	Successful target	[1]
BioChemical Class	Cytokine receptor
UniProt ID	INAR2_HUMAN
TTD ID	T06421
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS IVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF SCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK HKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE SAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD MVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI DPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR ITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT FPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR
Function	Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity. Associates with IFNAR1 to form the type I interferon receptor.
KEGG Pathway	Cytokine-cytokine receptor interaction (hsa04060 ) PI3K-Akt signaling pathway (hsa04151 ) Osteoclast differentiation (hsa04380 ) Toll-like receptor signaling pathway (hsa04620 ) Jak-STAT signaling pathway (hsa04630 ) Natural killer cell mediated cytotoxicity (hsa04650 ) Hepatitis C (hsa05160 ) Hepatitis B (hsa05161 ) Measles (hsa05162 ) Influenza A (hsa05164 ) Herpes simplex infection (hsa05168 )
Reactome Pathway	Regulation of IFNA signaling (R-HSA-912694 ) Interferon alpha/beta signaling (R-HSA-909733 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DTT

6 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anifrolumab	DM3FPAQ	Systemic lupus erythematosus	4A40.0	Approved	[2]
Interferon Alfa-2b, Recombinant	DM3TPY8	Hairy cell leukaemia	2A82.2	Approved	[3]
Interferon alfa-n1	DM4AK0Q	Chronic myelogenous leukaemia	2A20.0	Approved	[4]
Interferon alfacon-1	DM90WJH	Hepatitis C	1E51	Approved	[5]
Interferon beta-1b	DMCN61Z	Multiple sclerosis	8A40	Approved	[6]
Sifalimumab	DM1BS03	Renal cell carcinoma	2C90	Approved	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Approved Drug(s)

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alfa-interferon	DMXMK5S	Endometriosis	GA10	Phase 1	[7]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Endometriosis	GA10	Endometrium tissue	9.52E-01	-0.05	-0.17
Melanoma	2C82	Skin	4.55E-03	0.32	0.52
Myopathy	8A00.0	Muscle tissue	7.14E-01	0.1	0.52
Ovarian cancer	2C82	Ovarian tissue	4.80E-03	0.55	1.32
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of AstraZeneca (2009).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoie... Leuk Res. 2009 Aug;33(8):e111-3.
4	Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7.
5	Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46.
6	Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170.
7	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.